New cancer shot shows strong results in major skin cancer trial
Personalized mRNA vaccines helped lower the risk of death or cancer return by 42 percent in a large study of melanoma patients.
By Vanessa Diaz ·

A new personalized vaccine has shown promising results against one of the most dangerous forms of skin cancer.
Merck and Moderna announced Thursday that their mRNA vaccine reduced the risk of death or cancer recurrence by 42 percent. The study compared the vaccine against standard treatment alone. This significant drop in risk marks a major step forward in treating melanoma.
The companies are already talking to regulators to seek approval for the new therapy. The success of this trial also fuels broader hopes for the future of cancer care. Many experts believe individualized medicines and mRNA technology could reshape how doctors approach these diseases.
Stéphane Bancel, the CEO of Moderna, commented on the findings. He stated that the team believed from the start that mRNA could create treatments matched to specific tumors. He called the results a defining moment for that vision. Bancel added that the data shows what is possible when the approach to making medicines is rethought. He said the results reinforce the belief that mRNA can fundamentally change cancer treatment.
The partners first reported the vaccine’s success in August. They chose to hold back specific details until they could present the data at a scientific conference. That event is the European Society of Medical Oncology meeting in Madrid, Spain. The meeting started this week. The data was scheduled for presentation on Saturday. However, an oncology news site reported the results early. This broke the planned release timeline. The companies then released the top-line numbers. The full data set has been accepted for publication in the New England Journal of Medicine.
The Phase 3 trial involved 1,137 patients. All participants had stage IIB to IV melanoma. The cancer had been surgically removed before they entered the study. Doctors randomized the patients into two groups. Two-thirds received the combination treatment. This included the personalized mRNA vaccine along with standard care. One-third received only the standard treatment. The standard care was Merck’s established monoclonal antibody drug Keytruda.
The study design aimed to see if adding the vaccine improved outcomes over the existing standard of care. The 42 percent reduction in risk was measured against that baseline. The findings suggest the vaccine can be a powerful addition to current therapies. The rapid release of results highlights the importance of the data to the medical community. The presentation in Madrid remains the formal venue for the detailed scientific discussion.
For patients in the Great Lakes and Ohio Valley regions, the news offers a new option to discuss with their doctors. Melanoma remains a serious health concern, and new tools are always valuable. The collaboration between Merck and Moderna demonstrates how different companies can work together. Their combined resources helped bring this personalized approach to a late-stage trial. The next steps involve waiting for regulatory decisions and further publication of the full study.
The early leak of the results did not change the core findings. It did, however, accelerate the public announcement. The companies confirmed the numbers were accurate. The focus now shifts to how quickly the vaccine might reach clinics. The scientific community will continue to analyze the full data set. This trial stands out as a clear example of personalized medicine in action.






